Everolimus
Overview
Everolimus is an mTOR inhibitor and derivative of Sirolimus, used in the treatment of various types of cancer and in preventing organ transplant rejection. It acts by inhibiting the mammalian target of rapamycin (mTOR) pathway, which is involved in cell proliferation, angiogenesis, and metabolism.
API suppliers (9)
Suppliers of Everolimus evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 7 of 9 suppliers.
4 of 9 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- HANGZHOU HUADONG MEDICINE GROUP KANGRUN PHARMACEUTICAL CO LTDChina1 active DMF
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF GMP on record
- CHENGDU YACHT BIO-TECHNOLOGY CO LTDChina1 active DMF
- Biocon LimitedIndia1 active DMF
- Natco PharmaIndia1 active DMF GMP on record
- CONCORD BIOTECH LTDIndia1 active DMF GMP on record
- CHENGDU YACHT BIOTECHNOLOGY CO LTD1 active DMF
- SCINOPHARM TAIWAN LTDTaiwan
Patent & exclusivity (US)
Per the FDA Orange Book (72 approved US products), the latest listed US patent on Everolimus expires 1 Jul 2028. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Everolimus? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.